NEW YORK (GenomeWeb News) – MDxHealth today announced it has licensed certain DNA methylation biomarkers to Predictive Biosciences for the development of bladder cancer diagnostics.
Under the deal, Predictive has exclusive rights in the United States to use the biomarkers to develop the tests and will pay MDxHealth upfront and milestone payments as well as royalties on net sales.
MDxHealth, which is undergoing a restructuring, retains the worldwide exclusive rights to the markers for tissue-based bladder cancer tests. No further terms were disclosed.
"We believe that collaborating with partners who focus on one disease area is a better way to leverage our biomarkers for cancer screening as these dedicated companies stand a greater chance of bringing these products successfully to market," MDxHealth CEO Jan Groen said in a statement.